Evidence map›Paper›PMID 28261113›Full record

ArticleFrontiers in physiology2017

Validation of the CAchexia SCOre (CASCO). Staging Cancer Patients: The Use of miniCASCO as a Simplified Tool.

Josep M Argilés, Angelica Betancourt, Joan Guàrdia-Olmos, Maribel Peró-Cebollero, Francisco J López-Soriano, Clelia Madeddu, Roberto Serpe, Sílvia Busquets

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in physiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05915325 (Physical Training for Elderly Cancer Patients With Cachexia), which is not on this map. Cited by 36 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05915325 naactive not recruitingnot on this mapstarted 2023, after this paper: background citation

Physical Training for Elderly Cancer Patients With Cachexia (TEECH-01): a Prospective Clinical Trial

TypeinterventionalSponsorNational Cheng-Kung University HospitalRan2023 to 2026Enrolled23ConditionsGeriatric Assessment, Cancer, Cancer CachexiaArmsPhysical training
3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 1 synthesis or guideline pooled it, 75 citations in OpenAlex.

  1. Cancer- and cardiac-induced cachexia: same fate through different inflammatory mediators?Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2022
    Pooled it
  2. Observational
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Understanding cachexia and its impact on lung cancer and beyond.Chinese medical journal pulmonary and critical care medicine · 2024
    Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Josep M ArgilésCancer Research Group, Department of Biochemistry and Molecular Biomedicine, Faculty of Biology, University of BarcelonaBarcelona, Spain; Institute of Biomedicine (IBUB)Barcelona, Spain.
Angelica BetancourtCancer Research Group, Department of Biochemistry and Molecular Biomedicine, Faculty of Biology, University of Barcelona Barcelona, Spain.
Joan Guàrdia-OlmosAdvanced Statistical Data Analysis Applied to Psychology, Faculty de Psicology, University of BarcelonaBarcelona, Spain; Institute for Research on the Brain, Cognition and BehaviourBarcelona, Spain.
Maribel Peró-CebolleroAdvanced Statistical Data Analysis Applied to Psychology, Faculty de Psicology, University of BarcelonaBarcelona, Spain; Institute for Research on the Brain, Cognition and BehaviourBarcelona, Spain.
Francisco J López-SorianoCancer Research Group, Department of Biochemistry and Molecular Biomedicine, Faculty of Biology, University of BarcelonaBarcelona, Spain; Institute of Biomedicine (IBUB)Barcelona, Spain.
Clelia MadedduDepartment of Medical Oncology, University of Cagliari Cagliari, Italy.
Roberto SerpeDepartment of Medical Oncology, University of Cagliari Cagliari, Italy.
Sílvia BusquetsCancer Research Group, Department of Biochemistry and Molecular Biomedicine, Faculty of Biology, University of BarcelonaBarcelona, Spain; Institute of Biomedicine (IBUB)Barcelona, Spain.
Universitat de Barcelona · ESUniversity of Cagliari · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The CAchexia SCOre (CASCO) was described as a tool for the staging of cachectic cancer patients. The aim of this study is to show the metric properties of CASCO in order to classify cachectic cancer patients into three different groups, which are associated with a numerical scoring. The final aim was to clinically validate CASCO for its use in the classification of cachectic cancer patients in clinical practice. We carried out a case -control study that enrolled prospectively 186 cancer patients and 95 age-matched controls. The score includes five components: (1) body weight loss and composition, (2) inflammation/metabolic disturbances/immunosuppression, (3) physical performance, (4) anorexia, and (5) quality of life. The present study provides clinical validation for the use of the score. In order to show the metric properties of CASCO, three different groups of cachectic cancer patients were established according to the results obtained with the statistical approach used: mild cachexia (15 ≤ × ≤ 28), moderate cachexia (29 ≤ × ≤ 46), and severe cachexia (47 ≤ × ≤ 100). In addition, a simplified version of CASCO, MiniCASCO (MCASCO), was also presented and it contributes as a valid and easy-to-use tool for cachexia staging. Significant statistically correlations were found between CASCO and other validated indexes such as Eastern Cooperative Oncology Group (ECOG) and the subjective diagnosis of cachexia by specialized oncologists. A very significant estimated correlation between CASCO and MCASCO was found that suggests that MCASCO might constitute an easy and valid tool for the staging of the cachectic cancer patients. CASCO and MCASCO provide a new tool for the quantitative staging of cachectic cancer patients with a clear advantage over previous classifications.

Indexed as

anorexiacachexiaclassificationphysical performancequality of lifescorewastingweight loss

Identifiers

PMID28261113
PMCPMC5313479
OpenAlexW2588472851

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.